MR Fingerprinting of Adult Brain Tumors: Initial Experience

References

1. 1.↵
   2. Thakkar JP,
   3. Dolecek TA,
   4. Horbinski C, et al

   . Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev 2014;23:1985–96 doi:10.1158/1055-9965.EPI-14-0275 pmid:25053711

   Abstract/FREE Full Text
2. 2.↵
   2. Ostrom QT,
   3. Gittleman H,
   4. Liao P, et al

   . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 2014;16(suppl 4):iv1–63 doi:10.1093/neuonc/nou223 pmid:25304271

   FREE Full Text
3. 3.↵
   2. Nayak L,
   3. Lee EQ,
   4. Wen PY

   . Epidemiology of brain metastases. Curr Oncol Rep 2012;14:48–54 doi:10.1007/s11912-011-0203-y pmid:22012633

   CrossRefPubMed
4. 4.↵
   2. Sperduto PW,
   3. Chao ST,
   4. Sneed PK, et al

   . Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010;77:655–61 doi:10.1016/j.ijrobp.2009.08.025 pmid:19942357

   CrossRefPubMed
5. 5.↵
   2. Giese A,
   3. Bjerkvig R,
   4. Berens ME, et al

   . Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003;21:1624–36 doi:10.1200/JCO.2003.05.063 pmid:12697889

   Abstract/FREE Full Text
6. 6.↵
   2. Smith C,
   3. Ironside JW

   . Diagnosis and pathogenesis of gliomas. Current Diagnostic Pathology 2007;13:180–92 doi:10.1016/j.cdip.2007.04.002

   CrossRef
7. 7.↵
   2. Bulakbasi N,
   3. Kocaoglu M,
   4. Ors F, et al

   . Combination of single-voxel proton MR spectroscopy and apparent diffusion coefficient calculation in the evaluation of common brain tumors. AJNR Am J Neuroradiol 2003;24:225–33 pmid:12591638

   Abstract/FREE Full Text
8. 8.↵
   2. Cha S,
   3. Lupo JM,
   4. Chen MH, et al

   . Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2007;28:1078–84 doi:10.3174/ajnr.A0484 pmid:17569962

   Abstract/FREE Full Text
9. 9.↵
   2. Crisi G,
   3. Orsingher L,
   4. Filice S

   . Lipid and macromolecules quantitation in differentiating glioblastoma from solitary metastasis: a short-echo time single-voxel magnetic resonance spectroscopy study at 3 T. J Comput Assist Tomogr 2013;37:265–71 doi:10.1097/RCT.0b013e318282d2ba pmid:23493217

   CrossRefPubMed
10. 10.↵
    2. Fan G,
    3. Sun B,
    4. Wu Z, et al

    . In vivo single-voxel proton MR spectroscopy in the differentiation of high-grade gliomas and solitary metastases. Clin Radiol 2004;59:77–85 doi:10.1016/j.crad.2003.08.006 pmid:14697379

    CrossRefPubMed
11. 11.↵
    2. Halshtok Neiman O,
    3. Sadetzki S,
    4. Chetrit A, et al

    . Perfusion-weighted imaging of peritumoral edema can aid in the differential diagnosis of glioblastoma mulltiforme versus brain metastasis. Isr Med Assoc J 2013;15:103–05 pmid:23516772

    PubMed
12. 12.↵
    2. Kinoshita M,
    3. Goto T,
    4. Okita Y, et al

    . Diffusion tensor-based tumor infiltration index cannot discriminate vasogenic edema from tumor-infiltrated edema. J Neurooncol 2010;96:409–15 doi:10.1007/s11060-009-9979-0 pmid:19696968

    CrossRefPubMed
13. 13.↵
    2. Min ZG,
    3. Niu C,
    4. Rana N, et al

    . Differentiation of pure vasogenic edema and tumor-infiltrated edema in patients with peritumoral edema by analyzing the relationship of axial and radial diffusivities on 3.0T MRI. Clin Neurol Neurosurg 2013;115:1366–70 doi:10.1016/j.clineuro.2012.12.031 pmid:23351840

    CrossRefPubMed
14. 14.↵
    2. Price SJ,
    3. Jena R,
    4. Burnet NG, et al

    . Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. AJNR Am J Neuroradiol 2006;27:1969–74 pmid:17032877

    Abstract/FREE Full Text
15. 15.↵
    2. Ma D,
    3. Gulani V,
    4. Seiberlich N, et al

    . Magnetic resonance fingerprinting. Nature 2013;495:187–92 doi:10.1038/nature11971 pmid:23486058

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Jiang Y,
    3. Ma D,
    4. Seiberlich N, et al

    . MR fingerprinting using fast imaging with steady state precession (FISP) with spiral readout. Magn Reson Med 2015;74:1621–31 doi:10.1002/mrm.25559 pmid:25491018

    CrossRefPubMed
17. 17.↵
    2. Chen Y,
    3. Jiang Y,
    4. Pahwa S, et al

    . MR fingerprinting for rapid quantitative abdominal imaging. Radiology 2016;279:278–86 doi:10.1148/radiol.2016152037 pmid:26794935

    CrossRefPubMed
18. 18.↵
    2. Cicchetti DV

    . Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess 1994;6:284–90 doi:10.1037/1040-3590.6.4.284

    CrossRef
19. 19.↵
    2. Wong TZ,
    3. Van der Westhuizen GJ,
    4. Coleman RE

    . Positron emission tomography imaging of brain tumors. Neuroimaging Clin of N Am 2002;12:615–26 doi:10.1016/S1052-5149(02)00033-3 pmid:12687915

    CrossRefPubMed
20. 20.↵
    2. Pauleit D,
    3. Stoffels G,
    4. Bachofner A, et al

    . Comparison of 18 F-FET and 18 F-FDG PET in brain tumors. Nuclear Med Biol 2009;36:779–87 doi:10.1016/j.nucmedbio.2009.05.005 pmid:19720290

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Becherer A,
    3. Karanikas G,
    4. Szabó M, et al

    . Brain tumor imaging with PET: a comparison between [18F] fluorodopa and [11C] methionine. Eur J Nucl Med Mol Imaging 2003;30:1561–67 doi:10.1007/s00259-003-1259-1 pmid:14579097

    CrossRefPubMed
22. 22.↵
    2. Kamson DO,
    3. Juhász C,
    4. Buth A, et al

    . Tryptophan PET in pretreatment delineation of newly-diagnosed gliomas: MRI and histopathologic correlates. J Neurooncol 2013;112:121–32 doi:10.1007/s11060-013-1043-4 pmid:23299463

    CrossRefPubMed
23. 23.↵
    2. Clarke JL,
    3. Chang S

    . Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Cur Neurol Neurosci Rep 2009;9:241–46 doi:10.1007/s11910-009-0035-4 pmid:19348713

    CrossRefPubMed
24. 24.↵
    2. Henson JW,
    3. Ulmer S,
    4. Harris GJ

    . Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 2008;29:419–24 doi:10.3174/ajnr.A0963 pmid:18272557

    Abstract/FREE Full Text
25. 25.↵
    2. Gempt J,
    3. Soehngen E,
    4. Förster S, et al

    . Multimodal imaging in cerebral gliomas and its neuropathological correlation. Eur J Radiol 2014;83:829–34 doi:10.1016/j.ejrad.2014.02.006 pmid:24629350

    CrossRefPubMed
26. 26.↵
    2. Zhao B,
    3. Setsompop K,
    4. Ye H, et al

    . Maximum likelihood reconstruction for magnetic resonance fingerprinting. IEEE Trans Med Imaging 2016;35:1812–23 doi:10.1109/TMI.2016.2531640 pmid:26915119

    CrossRefPubMed
27. 27.↵
    2. Assländer J,
    3. Glaser SJ,
    4. Hennig J

    . Pseudo steady-state free precession for MR-fingerprinting. Magn Reson Med 2016 Apr 15. [Epub ahead of print] doi:10.1002/mrm.26202 pmid:27079826

    CrossRefPubMed
28. 28.↵
    2. Buonincontri G,
    3. Sawiak SJ

    . MR fingerprinting with simultaneous B1 estimation. Magn Reson Med 2016;76:1127–35 doi:10.1002/mrm.26009 pmid:26509746

    CrossRefPubMed
29. 29.↵
    European Society of Radiology (ESR). Magnetic resonance fingerprinting: a promising new approach to obtain standardized imaging biomarkers from MRI. Insights Imaging 2015;6:163–65 doi:10.1007/s13244-015-0403-3 pmid:25800993

    CrossRefPubMed
30. 30.↵
    2. Jiang Y,
    3. Ma D,
    4. Keenan KE, et al

    . Repeatability of magnetic resonance fingerprinting T1 and T2 estimates assessed using the ISMRM/NIST MRI system phantom. Magn Reson Med 2016 Oct 27. [Epub ahead of print] doi:10.1002/mrm.26509 pmid:27790751

    CrossRefPubMed
31. 31.↵
    2. Hamilton JI,
    3. Jiang Y,
    4. Chen Y, et al

    . MR fingerprinting for rapid quantification of myocardial T1, T2, and proton spin density. Magn Reson Med 2016 Apr 1. [Epub ahead of print] doi:10.1002/mrm.26216 pmid:27038043

    CrossRefPubMed
32. 32.↵
    2. Badve C,
    3. Yu A,
    4. Rogers M, et al

    . Simultaneous T1 and T2 brain relaxometry in asymptomatic volunteers using magnetic resonance fingerprinting. Tomography 2015;1:136–44 doi:10.18383/j.tom.2015.00166 pmid:26824078

    CrossRefPubMed
33. 33.↵
    2. Cloos MA,
    3. Alon L,
    4. Geppert C, et al

    . Rapid T1 and T2 mapping of the hip articular cartilage with radial MR fingerprinting. In: Proceedings of the Annual Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine, Toronto, Ontario, Canada. May 30 to June 5, 2015; Scientific Session: Cartilage Imaging (0113).
34. 34.↵
    2. Thomas RP,
    3. Xu LW,
    4. Lober RM, et al

    . The incidence and significance of multiple lesions in glioblastoma. J Neurooncol 2013;112:91–97 doi:10.1007/s11060-012-1030-1 pmid:23354652

    CrossRefPubMed
35. 35.↵
    2. Deoni SC

    . Quantitative relaxometry of the brain. Top Magn Reson Imaging 2010;21:101–13 doi:10.1097/RMR.0b013e31821e56d8 pmid:21613875

    CrossRefPubMed
36. 36.↵
    2. Opstad KS,
    3. Murphy MM,
    4. Wilkins PR, et al

    . Differentiation of metastases from high-grade gliomas using short echo time 1H spectroscopy. J Magn Reson Imaging 2004;20:187–92 doi:10.1002/jmri.20093 pmid:15269942

    CrossRefPubMedWeb of Science
37. 37.↵
    2. Maher EA,
    3. Furnari FB,
    4. Bachoo RM, et al

    . Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15:1311–33 doi:10.1101/gad.891601 pmid:11390353

    FREE Full Text
38. 38.↵
    2. Louis DN,
    3. Ohgaki H,
    4. Wiestler OD, et al

    . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109 pmid:17618441

    CrossRefPubMedWeb of Science
39. 39.↵
    2. Ma L,
    3. Song ZJ

    . Differentiation between low-grade and high-grade glioma using combined diffusion tensor imaging metrics. Clin Neurol Neurosurg 2013;115:2489–95 doi:10.1016/j.clineuro.2013.10.003 pmid:24183513

    CrossRefPubMed
40. 40.↵
    2. Kelly PJ,
    3. Daumas-Duport C,
    4. Kispert DB, et al

    . Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 1987;66:865–74 doi:10.3171/jns.1987.66.6.0865 pmid:3033172

    CrossRefPubMedWeb of Science
41. 41.↵
    2. Palfi S,
    3. Swanson KR,
    4. De Boüard S, et al

    . Correlation of in vitro infiltration with glioma histological type in organotypic brain slices. Br J Cancer 2004;91:745–52 pmid:15292940

    PubMedWeb of Science
42. 42.↵
    2. Deng Z,
    3. Yan Y,
    4. Zhong D, et al

    . Quantitative analysis of glioma cell invasion by diffusion tensor imaging. J Clin Neurosci 2010;17:1530–36 doi:10.1016/j.jocn.2010.03.060 pmid:20869249

    CrossRefPubMed
43. 43.↵
    2. Wang W,
    3. Steward CE,
    4. Desmond PM

    . Diffusion tensor imaging in glioblastoma multiforme and brain metastases: the role of p, q, L, and fractional anisotropy. AJNR Am J Neuroradiol 2009;30:203–08 pmid:18842762

    Abstract/FREE Full Text
44. 44.↵
    2. Watanabe M,
    3. Tanaka R,
    4. Takeda N

    . Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology 1992;34:463–69 doi:10.1007/BF00598951 pmid:1436452

    CrossRefPubMedWeb of Science
45. 45.↵
    2. Wagnerova D,
    3. Herynek V,
    4. Malucelli A, et al

    . Quantitative MR imaging and spectroscopy of brain tumours: a step forward? Eur Radiol 2012;22:2307–18 doi:10.1007/s00330-012-2502-6 pmid:22688126

    CrossRefPubMed
46. 46.↵
    2. Damadian R

    . Tumor detection by nuclear magnetic resonance. Science 1971;171:1151–53 doi:10.1126/science.171.3976.1151 pmid:5544870

    Abstract/FREE Full Text
47. 47.↵
    2. Araki T,
    3. Inouye T,
    4. Suzuki H, et al

    . Magnetic resonance imaging of brain tumors: measurement of T1—work in progress. Radiology 1984;150:95–98 doi:10.1148/radiology.150.1.6689793 pmid:6689793

    CrossRefPubMedWeb of Science
48. 48.↵
    2. Komiyama M,
    3. Yagura H,
    4. Baba M, et al

    . MR imaging: possibility of tissue characterization of brain tumors using T1 and T2 values. AJNR Am J Neuroradiol 1987;8:65–70 pmid:3028112

    Abstract/FREE Full Text
49. 49.↵
    2. Just M,
    3. Thelen M

    . Tissue characterization with T1, T2, and proton density values: results in 160 patients with brain tumors. Radiology 1988;169:779–85 doi:10.1148/radiology.169.3.3187000 pmid:3187000

    CrossRefPubMedWeb of Science
50. 50.↵
    2. Kjaer L,
    3. Thomsen C,
    4. Gjerris F, et al

    . Tissue characterization of intracranial tumors by MR imaging. In vivo evaluation of T1- and T2-relaxation behavior at 1.5 T. Acta Radiol 1991;32:498–504 doi:10.1177/028418519103200612 pmid:1742132

    Abstract/FREE Full Text
51. 51.↵
    2. Newman S,
    3. Haughton V,
    4. Yetkin Z, et al

    . T1, T2 and proton density measurements in the grading of cerebral gliomas. Eur Radiol 1993;3:49–52
52. 52.↵
    2. Ellingson BM,
    3. Cloughesy TF,
    4. Lai A, et al

    . Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J Neurooncol 2012;106:111–19 doi:10.1007/s11060-011-0638-x pmid:21706273

    CrossRefPubMed
53. 53.↵
    2. Lescher S,
    3. Jurcoane A,
    4. Veit A, et al

    . Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI. Neuroradiology 2015;57:11–20 doi:10.1007/s00234-014-1445-9 pmid:25287076

    CrossRefPubMed
54. 54.↵
    2. Hattingen E,
    3. Jurcoane A,
    4. Daneshvar K, et al

    . Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival. Neuro Oncol 2013;15:1395–404 doi:10.1093/neuonc/not105 pmid:23925453

    Abstract/FREE Full Text
55. 55.↵
    2. Ellingson BM,
    3. Lai A,
    4. Nguyen HN, et al

    . Quantification of nonenhancing tumor burden in gliomas using effective T2 maps derived from dual-echo turbo spin-echo MRI. Clin Cancer Res 2015;21:4373–83 doi:10.1158/1078-0432.CCR-14-2862 pmid:25901082

    Abstract/FREE Full Text
56. 56.↵
    2. Ma D,
    3. Hamilton J,
    4. Jiang Y, et al

    . Fast 3D magnetic resonance fingerprinting (MRF) for whole brain coverage in less than 3 minutes. In: Proceedings of the Annual Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine, Singapore. May 7–13, 2016; Electronic Poster Session: Acquisition, Reconstruction and Analysis 1 (3180)